Teleflex(US:TFX)2025-07-31 12:00Q2 2025 Performance - Adjusted constant currency revenue grew by 1.0% year-over-year[12] - Adjusted gross margin was 59.7%[12] - Adjusted operating margin was 26.9%[12] - Adjusted EPS reached $3.73, a 9.1% increase year-over-year[12] 2025 Financial Guidance - Adjusted constant currency revenue growth guidance increased to a range of 7.70% to 8.70%, compared to the prior range of 1.00% to 2.00%[12] - Adjusted diluted EPS from continuing operations guidance increased to a range of $13.90 to $14.30, compared to the prior range of $13.20 to $13.60[12] - GAAP Revenue Growth is forecasted between 9.00% and 10.00%[41] Segment Performance (Q2 2025) - Americas reported revenue of $525.7 million, with adjusted constant currency revenue growth of 2.0%[13, 14] - EMEA reported revenue of $166.2 million, but experienced an adjusted constant currency revenue decline of 2.1%[13, 14] - Asia reported revenue of $89.0 million, with adjusted constant currency revenue growth of 1.2%[13, 14] Strategic Updates - Teleflex is progressing with the separation into RemainCo and NewCo, and is evaluating a potential sale of NewCo[23] - Teleflex completed the acquisition of BIOTRONIK's Vascular Intervention business for an initial upfront cash payment of €704 million[23]